NeoDynamics awarded SEK 4 million from Vinnova
STOCKHOLM, SWEDEN – APRIL 3, 2012. NeoDynamics AB, a Karolinska Development portfolio company, has been awarded 4 million from Vinnova for their program Forska&Väx. The program is aimed at small and medium size companies in all industries that independently, or in collaboration with partners, can demonstrate a strong growth potential by investing in research, development and innovation.
"We are very pleased that Vinnova has chosen to support our development of the new and innovative precision based biopsy product named Fourier. This grant will enable NeoDynamics to speed up development and bring the product to the market”, says Peter Sellei, CEO, NeoDynamics AB.
Vinnova's research grants is aimed at companies who – in-house or together with external partners – have projects that meet a market need and aims to promote the development of new or improved products, services and processes for the customer. The project should be associated with the applicant company's business and to be based on solid market. The project aims to strengthen the company's growth potential and competitiveness on the Swedish as well as the international market.
For further information, please contact:
Peter Sellei, CEO, NeoDynamics AB
Tel: +46 (0)70 624 21 89, email: firstname.lastname@example.org
NeoDynamics is a Swedish medical technology company developing equipment to diagnose and treat breast cancer on the same day. The company's technologies for diagnosis and treatment are currently undergoing clinical trials. NeoDynamics' goal is to develop further prototypes for clinical use and enter partnerships that ensure commercialisation and global expansion. www.neodynamics.se
About Karolinska Development
Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations. Today, the portfolio consists of 36 projects, of which 14 are in clinical development. For more information, please visit www.karolinskadevelopment.com.